Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Abbott Laboratories

Related ABT
5 Companies That Have Moved Overseas For Lower Taxes
Bet On This Top Ranked Medical Device ETF - ETF News And Commentary
Buyback Mania Inflates 2Q Earnings Growth (Fox Business)

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Abbott Laboratories (NYSE: ABT).

Morgan Stanley noted, “The critical debates on the new Abbott are: (i) feasibility of upper-single-digit growth, (ii) magnitude of operating leverage and visibility of double-digit earnings growth and (iii) whether a valuation inefficiency exists. We believe Abbott has set expectations at a fair level and is likely to hit targets for mid- to high-single-digit revenue and 10%+ EPS growth.”

Abbott Laboratories closed on Friday at $65.53.

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters